What is Castle Biosciences's cash ratio?

Castle Biosciences (CSTL) reported cash ratio of 1.3× in Q1 2026.

How has Castle Biosciences's cash ratio changed year-over-year?

Castle Biosciences's cash ratio decreased by 45.7% year-over-year, from 2.4× to 1.3×.

What is the long-term trend for Castle Biosciences's cash ratio?

Over 5 years (2020 to 2025), Castle Biosciences's cash ratio has grown at a -38.7% compound annual growth rate (CAGR), from 19.6× to 1.7×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Castle Biosciences CSTL Cash ratio

Cash ratio at other companies

Labcorp HoldingsLH

0.4×+0.2×

VeracyteVCYT

4.7×+2.2×

Personalis, Inc.PSNL

1.9×-0.5×

NeoGenomicsNEO

1.7×+0.5×

Fulgent Genetics, Inc.FLGT

0.3×-0.8×

Cogent Biosciences, Inc.COGT

4.2×+1.6×

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Calculated from Castle Biosciences’s reported figures.

cash and equivalents/total current liabilities=1.3×

Based on the most recent quarter.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's cash ratio?: Castle Biosciences (CSTL) reported cash ratio of 1.3× in Q1 2026.
How has Castle Biosciences's cash ratio changed year-over-year?: Castle Biosciences's cash ratio decreased by 45.7% year-over-year, from 2.4× to 1.3×.
What is the long-term trend for Castle Biosciences's cash ratio?: Over 5 years (2020 to 2025), Castle Biosciences's cash ratio has grown at a -38.7% compound annual growth rate (CAGR), from 19.6× to 1.7×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.